Xlife Sciences AG (XSWX:XLS) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:XLS Xlife Sciences AG XSWX:XLS
52 GF Score
Price CHF16.80
GF Value CHF7.17
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

XSWX:XLS
52GF Score
Xlife Sciences AG XSWX:XLS
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF16.80 is trading 134.3% above its estimated GF Value™ of CHF7.17. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Dividend-Payout-to-FFO:
  • GF Value™: CHF7.17 vs. price of CHF16.80 (134.3% above fair value)
  • GF Score™: 52/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
52GF Score

Get the complete analysis for XSWX:XLS

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF16.80
Price
CHF7.17
GF Value